Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice-Reference-Cited by-同舟云学术

Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice

Published:2020-01-07 Issue:5 Volume:25 Page:899-905
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Tamura Daichi^ORCID,Jinnouchi Noriaki,Abe Masakazu,Ikarashi Daiki,Matsuura Tomohiko,Kato Renpei,Maekawa Shigekatsu,Kato Yoichiro,Kanehira Mitsugu,Takata Ryo,Obara Wataru

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-019-01613-9.pdf

Reference29 articles.

1. Torre LA, Bray F, Siegel RL et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108

2. Seront E, Machiels JP (2015) Molecular biology and targeted therapies for urothelial carcinoma. Cancer Treat Rev 41:341–353

3. Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:1015–1026

4. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674

5. Selders GS, Fetz AE, Radic MZ et al (2017) An overview of the role of neutrophils in innate immunity, inflammation and host-biomaterial integration. Regen Biomater 4:55–68

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of adjuvant nivolumab after radical surgery for high-risk urothelial carcinoma: a preliminary report of real-world data from a single institution;International Journal of Clinical Oncology;2024-09-12

2. Prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with durvalumab with or without tremelimumab in the DANUBE study;Clinical Genitourinary Cancer;2024-09

3. Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis;Immunotherapy;2024-08-19

4. Prognostic role of circulating cytokines and inflammation indexes for avelumab maintenance in metastatic urothelial carcinoma;Frontiers in Immunology;2024-05-10

5. Pre-first-line chemotherapy risk stratification for overall survival in advanced urothelial carcinoma in sequential therapy era;World Journal of Urology;2024-05-09